Skip to main content

Table 1 ANXA1 expression and clinical variables

From: Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

  BCAC patients   BRCA1|2 mutation carriers  
ANXA1 negative ANXA1 positive ANXA1 negative ANXA1 positive
n % n % P valuea n % n % P valueb P valuec
5,040 87.6 712 12.4   55 51.4 52 48.6   <0.0001
Age of diagnosis      <0.0001      0.2253 0.0401
 <50 years old 2,462 85.6 413 14.4   34 47.2 38 52.8   
 ≥50 years old 2,578 89.6 299 10.4 21 60.0 14 40.0
 Missing 0   0    0   0    
BRCA status      0.0026      0.0583  
 Non-carrier 858 83.6 168 16.4        
BRCA1 11 61.1 7 38.9 25 42.4 34 57.6  
BRCA2 14 73.7 5 26.3 30 62.5 18 37.5
 Missing 3,812   430    0   0    
Menopausal status      0.0330       
 Pre- 1,556 86.2 250 13.8        
 Post- 2,258 88.3 298 11.7     
 Missing 1,226   164         
Morphology      <0.0001      0.5946 0.0235
 Ductal 3,558 86.2 568 13.8   33 50.8 32 49.2   
 Lobular 710 94.3 43 5.7 11 61.1 7 38.9
 Missing 772   101    11   13    
Grade      <0.0001      0.0040 0.1460
 1 1,129 95.0 59 5.0   7 77.8 2 22.2   
 2 2,246 92.8 173 7.2 26 66.7 13 33.3
 3 1,306 75.2 431 24.8 19 35.8 34 64.2
 Missing 359   49    3   3    
Tumor size      <0.0001      0.9910 0.7780
 ≤2 cm 2,809 88.8 354 11.2   31 51.7 29 48.3   
 >2 cm and ≤5 cm 1,610 86.5 252 13.5 19 52.8 17 47.2
 >5 cm 109 79.9 29 21.0 2 50.0 2 50
 Missing 512   77   3   4  
Node status      0.2725       
 Negative 2,669 87.1 395 12.9   31 47.0 35 53.0 0.3044 0.1790
 Positive 1,955 88.1 263 11.9   22 59.5 15 40.5   
 Missing 416   54   2   2  
ER status      <0.0001       
 Negative 977 67.8 465 32.2   13 28.3 33 71.7 <0.0001 0.7373
 Positive 3,796 95.0 200 5.0   36 75.0 12 25.0   
 Missing 267   47   6   7  
PR status      <0.0001       
 Negative 1,435 75.9 455 24.1   20 35.1 37 64.9 <0.0001 0.1670
Positive 3,159 94.8 175 5.2   27 77.1 8 22.9   
 Missing 446   82   8   7  
HER2 status      0.1328       
 Negative 3,484 88.7 442 11.3   25 48.1 27 51.9 1.0000 0.0684
 Positive 643 86.8 98 13.2   1 50.0 1 50.0   
 Missing 913   172   29   24  
EGFR-CK5/6 statusd      <0.0001       
 Negative 3,317 93.8 218 6.2        
 Positive 541 67.6 259 32.4        
 Missing 1,182   235      
p53 statuse      0.0572       
 Negative 172 90.1 19 9.9   17 45.9 20 54.1 0.0211 0.8116
 Positive 57 80.3 14 19.7   3 14.3 18 85.7   
 Missing 596   89   35   14  
Adjuvant chemotherapy      <0.0001       
 No 2,593 89.9 282 10.1        
 Yes 1,585 83.2 320 16.8        
 Missing 862   100      
Adjuvant hormonal therapy      <0.0001       
 No 2,059 82.5 438 17.5        
 Yes 2,562 92.6 204 7.4        
 Missing 419   70        
  1. Distribution of the clinical variables in breast cancer patients according to the ANXA1 expression in all invasive tumors from the BCAC and BRCA1|2 set of patients
  2. ANXA1 annexin A1, BCAC Breast Cancer Association Consortium, EGFR epidermal growth factor receptor
  3. aP value of the comparison between ANXA1 positive and negative patients in the BCAC set
  4. bP value of the comparison between ANXA1 positive and negative patients in the BRCA1|2 mutated set
  5. cP value of the comparison between the two sets of ANXA1 positive patients: BCAC and BRCA1|2 mutated patients
  6. dEGFR-CK5/6 status was defined as positive when CK5/6 and/or EGFR were positive
  7. ein the BCAC set, p53 status information was only available for the ABCS study
\